Glecaprevir + Pibrentasvir

Glecaprevir + Pibrentasvir

Form: Tablet

Strength: Glecaprevir- 100 mg + Pibrentasvir - 40 mg

Reference Brands: Mavyret (US); Maviret (EU)

Category: Anti Viral

Mavyret (US) / Maviret (EU) is a fixed-dose combination of Glecaprevir 100 mg and Pibrentasvir 40 mg per tablet, approved by the FDA and EMA for the treatment of chronic hepatitis C virus (HCV) infection across genotypes 1–6. This pan-genotypic regimen is taken as three tablets once daily with food. It offers one of the shortest HCV treatments—just 8 weeks for most patients. Mavyret is highly effective (SVR >95%) and suitable for use in patients with renal impairment and compensated cirrhosis. Its ribavirin-free formulation improves tolerability, making it a convenient, high-efficacy option for diverse patient populations.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Zanamivir

Strength: 5 mg/blister

Form: Inhalation powder

Reference Brands: Relenza(EU & US)

View Details Get Enquiry
Oseltamivir Phosphate Capsule

Strength: Capsule- 30 mg, 45 mg, 75 mg; Oral Suspension - 6 mg/mL (reconstituted)

Form: Capsules and Oral solution

Reference Brands: Tamiflu(EU & US)

View Details Get Enquiry
Amantadine

Strength: Tab -100 mg; Capsule- 100 mg; Oral solution - 50 mg/5 mL; Extended-release capsule (ER) - 129 mg, 193 mg

Form: Tablet; Capsule; Oral Solution and ER Capsule

Reference Brands: Symmetrel(EU & US); Osmolex ER(US), Gocovri(US)

View Details Get Enquiry
Velpatasvir + Sofosbuvir

Strength: Sofosbuvir - 400 mg + Velpatasvir - 100 mg

Form: Tablet

Reference Brands: Epclusa(US & EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.